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Scaffold attachment factor B1 (SAFB1) and SAFB2 proteins are oestrogen (ER) corepressors that bind to and modulate ER activity
through chromatin remodelling or interaction with the basal transcription machinery. SAFB proteins also have an internal
RNA-recognition motif but little is known about the RNA-binding properties of SAFB1 or SAFB2. We utilised crosslinking
and immunoprecipitation (iCLIP) coupled with high-throughput sequencing to enable a transcriptome-wide mapping of SAFB1
protein-RNA interactions in breast cancer MCF-7 cells. Analysis of crosslinking frequency mapped to transcript regions revealed
that SAFB1 binds to coding and noncoding RNAs (ncRNAs). The highest proportion of SAFB1 crosslink sites mapped to ncRNAs,
followed by intergenic regions, open reading frames (ORFs), introns, and 3󸀠 or 5󸀠 untranslated regions (UTR). Furthermore, we
reveal that SAFB1 binds directly to RNA and its binding is particularly enriched at purine-rich sequences not dissimilar to the
RNA-binding motifs for SR proteins. Using RNAi, we also show, for the first time, that single depletion of either SAFB1 or SAFB2
leads to an increase in expression of the other SAFB protein in both MCF-7 and MDA-MD231 breast cancer cells.
1. Introduction
Thegrowing interest in SAFB1 and SAFB2 proteins in relation
to cancer is generated from their well described ability to
bind to and modulate ER-𝛼, a central player in breast cancer
development. Moreover, a role for SAFB1 in RNA splicing
and metabolism has also been proposed. Nayler et al. [1] first
described interactions between SAFB1 with RNA polymerase
II and a subset of serine/arginine-richRNAprocessing factors
(SR proteins) suggesting that SAFB1 serves as a molecular
base for the assembly of a transcriptome complex that couples
chromatin organising S/MARs elements with transcription
and pre-mRNA processing [1]. Protein-protein interactions
between SAFB1 and a range of RNA-binding proteins includ-
ing hnRNP A1, hnRNP D, hnRNP G, SR splicing regulatory
protein 86 (SRrp86), SR protein kinase 1 (SRPK1), and Src-
associated substrate in mitosis of 68 kDa (Sam68) provide
reasonable evidence to implicate a role in alternative splicing
[2–6]. However, it is still not known whether these SAFB
proteins exert their effects on pre-mRNA splicing through
direct RNA interaction or by tethering to other splicing
factors.
SAFB1 and SAFB2 proteins share a highly conserved
RNA-recognition motif (RRM) with 98% similarity in the
central region, although until now their direct RNA-binding
potential has remained unclear. SAFB1 has also been labelled
as a novel hnRNP protein due to its similarity to the highly
conserved RBD found in the hnRNP protein family [6].
Subsequent studies have implicated both SAFB proteins in
alternative splicing, as overexpression of SAFB1 and SAFB2
inhibits splicing of a TRA2B variable exon [5, 7]. However,
further investigation usingmutants lacking the RRM domain
revealed that SAFB1’s ability to inhibit TRA2B exon skipping
was independent of its RNA-binding ability [7].This evidence
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suggests that SAFB1 may not bind directly to TRA2B pre-
mRNA to regulate exon skipping but could possibly mediate
an indirect effect through its interaction with various splicing
factors [2, 4–6]. In an unrelated study, in vitro evidence has
shown that the RRM domain of SAFB1 was able to bind RNA
isolated fromMCF-7 breast cancer cells, although the identity
of the RNA targets was not described [8]. The current study
was designed to establish whether SAFB proteins exert their
RNA processing functions through direct RNA interaction as
well as by tethering to other protein factors.
2. Material and Methods
2.1. iCLIP. CLIP with individual nucleotide resolution
(iCLIP) was performed for SAFB1 usingMCF-7 breast cancer
cells based on a published protocol [9]. In brief, MCF-7 cells
were irradiated with 150mJ/cm2 of UV at 254 nm and cell
pellets resuspended in lysis buffer treated with Turbo DNase
I (Ambion) and high (1 : 10 dilution) or low (1 : 500 dilution)
RNase I (Ambion). Dynabeads Protein A or Dynabeads
Protein G (Invitrogen) were resuspended in lysis buffer con-
taining 5𝜇g SAFB1 antibody (Sigma-Aldrich) and precleared
lysate was added to themagnetic beads for immunoprecipita-
tion at 4∘C for 2 hours. RNA 3󸀠 ends were dephosphorylated
and RNA linkers ligated. Magnetic beads were then resus-
pended in PNK mix containing 32P-𝛾-ATP to radioactively
label the RNA 5󸀠 ends, as previously described [9]. Protein-
RNA complexes were isolated following electrophoresis (see
Supplementary Figure 1 in Supplementary Material available
online at http://dx.doi.org/10.1155/2015/395816). Precipitated
RNA was reverse transcribed in RNA/primer mix containing
different Rclip primers with individual barcode sequences
for each replicate. Three gel fragments corresponding to
cDNA size were cut at 120–200 nucleotides (high), 85–
120 nucleotides (medium), and 70–85 nucleotides (low)
(Supplementary Figure 1(B)). Three independent biological
replicates were prepared for sequencing using the TruSeq
Sample Preparation kit (Illumina) and sequenced on the
GenomeAnalyser II system (GAIIx, Illumina). Bioinformatic
analyses were performed on the web-based iCount software
(http://icount.biolab.si/). Mapping of SAFB1 crosslink sites
to regions of respective genes was visualised in UCSC
Genome Browser (http://genome.ucsc.edu/) and a graphi-
cal representation of the novel SAFB1 consensus binding
motif was designed using the web-based WebLogo soft-
ware (http://weblogo.berkeley.edu/). Potential target genes
that contain SAFB1 binding sites were selected for further
validation using qRT-PCR with TaqMan gene expression
assays.
2.1.1. Transient Transfections. MCF-7 andMDA-MB-231 cells
were reverse transfected with two independent sets of
Silencer Select siRNA for SAFB1 and SAFB2, Silencer Neg-
ative Control siRNA, Silencer Select GAPDH, and 𝛽-actin
Positive Control siRNA (Life Technologies) using INTER-
FERin Transfection Agent (Polyplus transfection) according
to the manufacturer’s instructions. Following optimisation,
cells were seeded at 3.5 × 104 cells/well in 24-well plates
or 1.75 × 105 cells/well into 6-well plates. After 24 hours,
cells were transfected with 5 nM siRNA with 4𝜇L/mL of
INTERFERin transfection agent. RNA was collected 48 and
72 hours after transfection and protein collected 72 hours
after transfection. In all experiments, levels of knockdown by
RNAi were assessed at the RNA and protein level by PCR and
immunoblotting.
2.1.2. RNA Isolation and PCR. Total RNA from cultured
cells was extracted with RNeasy spin columns (Qiagen) or
the SV Total RNA Isolation System (Promega) according
to manufacturer’s instructions. One 𝜇g of total RNA was
reverse transcribed using oligo (dT) primers and Superscript
II Reverse Transcriptase (RT) (Invitrogen, Life Technologies)
following manufacturer’s instructions. Conventional PCR
was performed using PCR master mix (Promega). qPCR was
performed using TaqMan gene expression assays (Life Tech-
nologies) according to the manufacturer’s instructions. Val-
idated TaqMan probes were selected to target specific genes
as follows: SAFB1 (Hs01561652 gl), SAFB2 (Hs01006796 g1),
ITGB4 (Hs00236216 m1), SHF (Hs00403125 m1), MALAT-
1 (Hs00273907 s1), and 𝛽-actin (Hs99999903 m1). Data
analysis was performed using the comparative Ct method
normalised against 𝛽-actin expression. Experiments were
performed in triplicate and statistical analysis was performed
using Student’s 𝑡-test or Repeated Measures ANOVA with
Dunnett’s Multiple Comparison Test. All effects at 𝑃 < 0.05
are reported as significant.
2.2. RNA Immunoprecipitation. MCF-7 cells were washed in
ice cold PBS and then collected in lysis buffer (10mM Tris-
HCl (pH 7.5), 150mM NaCl, 0.5% NP-40, and 1% Triton
X-100) containing protease inhibitors (Sigma-Aldrich) and
RNase OUT (Invitrogen). Equal amounts of cell lysate were
then incubated for 3 hours at 4∘C with 2𝜇g of either rabbit
anti-SAFB1 antibody (Genetex) or rabbit IgG control (Santa
Cruz). Cell lysates and antibodies were then incubated with
Dynabeads Protein G (Invitrogen) for a further hour at 4∘C.
Beads were then washed five times with lysis buffer before
the immunoprecipitated RNA was collected in Trizol reagent
(Invitrogen) according to manufacturer’s instructions. The
RT-PCR was performed as before but half of the RNA
obtained from the immunoprecipitation was used in each
reaction. Fold enrichment of target mRNA was determined
after normalization to the input and rabbit IgG controls.
3. Results
3.1. Identification of RNA-Binding Sites for SAFB1 in Breast
Cancer Cells. Although the role of SAFB proteins in RNA
processing has been speculated, the function of their highly
homologous internal RRM has not been examined. We
sought to identify possible direct RNA targets for SAFB1 in
breast cancer cells, using iCLIP technology [9–12] combined
with high-throughput sequencing and mapping to generate a
transcriptome-wide binding map for SAFB1. SAFB1 protein-
RNA complexes were successfully generated by immuno-
precipitation and RNA recovered and purified from 3 inde-
pendent iCLIP replicates (Supplementary Figure 1). High-
throughput sequencing and bioinformatics generated a total
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Figure 1: Distribution of significant SAFB1 crosslink sites within RNA segment types. (a) The proportion of cDNAs mapped to different
transcript regions relative to the total number of cDNA reads revealed that the highest percentage of cDNAs was mapped to ncRNA (47.08%),
followed by intergenic regions (23.24%), ORFs (19.38%), introns (5.23%), 3󸀠 UTRs (3.83%), and 5󸀠 UTRs (0.86%). (b) The fold enrichment
of cDNA density in different types of RNAs relative to cDNA density in the whole genome highest density enrichment in ncRNAs. (c) The
distribution of SAFB1 crosslink sites within different ncRNA subclasses revealed significant abundance in snRNA, Mt RNA, and snoRNA.
“Other RNA” consists of pseudogenes and processed transcripts with no known ORF or function.
of 1,145,271 unique cDNA reads with single-hits mapping to
the human genome which were subsequently filtered down
to 587,119 significant unique cDNAs distributed over 127308
binding sites in 25207 SAFB1 crosslink clusters (FDR < 0.05).
A snapshot of the view for SAFB1 crosslink sites on the
UCSC Genome Browser (http://genome.ucsc.edu/) is shown
in Supplementary Figure 1(C).
iCLIP identified binding sites for SAFB1 across the
whole transcriptome, where 100% of significant cDNA reads
mapped to the sense orientation in annotated genes. This
confirms the high strand specificity of iCLIP also observed
in other studies [11, 13]. Analysis of crosslinking frequency
mapped to transcript regions revealed that SAFB1 binds to
coding and noncoding RNAs (ncRNAs). Notably, the highest
proportion of 127308 SAFB1 crosslink sites from significant
clusters map to ncRNAs followed by intergenic regions, open
reading frames (ORFs), introns, and 3󸀠 or 5󸀠 untranslated
regions (UTRs) (Figure 1(a)). When the cDNA density for
each transcript region was analysed relative to the cDNA
density in the whole genome, the highest density enrichment
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Figure 2: In vivo consensus binding motif of SAFB1. (a) The frequency of pentamers surrounding SAFB1 crosslink sites was determined.
Adenine represents 68%of the 20 pentamers that has the highest frequencies. (b)WebLogo showing base frequencies of each base at respective
positions of the pentamer. SAFB1 binds to adenine-rich motifs. (c) The frequency of each base relative to its position within the pentamer
was summarised in this table. The highest frequency of adenine was observed at base position 5; thymine was excluded at base position 4 of
the consensus binding motif. This consensus binding motif was predicted from iCLIP cDNA libraries; therefore the uracil base is referred to
as thymine in these sequences.
was detected in ncRNAs (Figure 1(b)). The distribution of
SAFB1 crosslink sites within ncRNA subclasses was also
analysed. SAFB1 crosslink sites were most abundant in small
nuclear RNA (snRNA), mitochondrial RNA (Mt RNA), and
small nucleolar RNA (snoRNA) (Figure 1(c)).
3.2. Identification of an RNA-Binding Motif for SAFB1. The in
vivo binding specificity of SAFB1 is still currently unknown.
The advantage of single nucleotide resolution provided by
iCLIPmethod enabled the assessment of sequence specificity
for SAFB1 binding. To derive whether a consensus binding
motif exists for SAFB1, enriched pentamer sequences sur-
rounding the crosslink sites were identified. The frequencies
of each pentamer were analysed to determine the top 20
pentamers for SAFB1. Strikingly, adenine appeared as the
most frequent nucleotide in the top 20 pentamers and
represents 68% of the enriched pentamers (Figure 2(a)). The
predicted SAFB1 consensus binding motif contains adenine-
rich sequences derived from the pentamers (Figure 2(b)).
When the frequency of each nucleotide in the cDNA libraries
was analysed relative to its base position, a strong inclusion of
adenine at base position 5 was observed (80%) while thymine
(uracil inRNA)was excluded at base position 4 of the putative
RNA-binding motif (Figure 2(c)). The consensus binding
motif for SAFB1 has not been described before; therefore,
this novel finding is likely to be of significance to further our
current understanding of SAFB1 RNA-binding specificity.
3.3. Identification of Novel RNA Targets from Data Generated
by iCLIP. Data analysis of bound RNAs revealed the number
of SAFB1 crosslink sites within each RNA target. When the
top 10 RNA targets with the largest number of crosslink sites
were listed according to each RNA segment, the position
of SAFB1 binding within each gene was visualised using
the UCSC Genome Browser (Supplementary Figure 2). This
enabled the identification of several interesting RNA targets
that were selected for validation. Further experimentations
were performed using qRT-PCR or conventional PCR on
RNAi transfectedMCF-7 andMDA-MB-231 cells to verify the
effect of loss of SAFB1 on the expression of these selectedRNA
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Figure 3: Loss of SAFB proteins affects expression of SHF and ITGB4. Knockdown of SAFB1 in MCF-7 cells increases mRNA and protein
expression of SAFB2 and similarly knockdown of SAFB2 leads to increased expression of SAFB1. MC7-7 cells were transiently transfected
with negative, SAFB1, SAFB2 or SAFB1 and SAFB2 siRNA. mRNA levels were measured by qRT-PCR. Data represents the average of three
biological replicates ± SD. Statistical significance of mRNA expression was calculated using Student’s 𝑡-test; ∗ = 𝑃 < 0.05. (b) Protein levels
were analysed by immunoblotting using SAFB1 and SAFB2 antibodies. (c) The effect of SAFB knockdown on SHF and ITGB4 expression by
qRT-PCR using validated TaqMan probes specifically targeting SHF (c) or ITGB4 (d). Data represents the average of three biological replicates
± SD. Statistical significance of mRNA expression was calculated using Student’s 𝑡-test; 𝑃 < 0.05.
targets. Since SAFB2 shares 98% sequence homology to the
RRM of SAFB1, these cells were also depleted of SAFB2 and
double knockdown of SAFB1 and SAFB2 was also included;
interestingly, data shows that when MCF-7 cells are reduced
of SAFB1 by RNAi, the levels of SAFB2 mRNA and protein
increase (Figure 3(a)). Likewise, levels of SAFB1 increase after
knockdown of SAFB2 (Figure 3(b)). A similar pattern was
observed when the breast cancer MDA-MB-231 cells were
used (Supplementary Figure 3).
Analysis of the RNA map revealed a large number of
SAFB1 binding sites on the SHF mRNA, particularly accu-
mulated around the alternative promoter (Supplementary
Figure 3); the use of alternative promoters plays a significant
role in gene expression control (reviewed in [14–16]). More
importantly, the aberrant use of alternative promoter has
been linked to a number of diseases, including cancer [17].
Therefore, identification of SHF as a potential RNA target for
SAFB1 warrants further investigation. In MCF-7 noninvasive
breast cancer cells, a reduction in SAFB1 did not appear to
significantly alter SHF mRNA expression, whereas in MDA-
MB-231 invasive breast cancer cells there was a significant
increase in SHFmRNA expression when SAFB1 was reduced
(Figure 3(c)). Loss of SAFB2 and both SAFB proteins by
RNAi increased SHF expression, again supporting their role
as transcriptional repressors. Another potential RNA target
for SAFB proteins is ITGB4. The observed loss of SAFB1
in both breast cancer cell lines does not have an effect
on ITGB4 mRNA expression whereas loss of SAFB2 and
both SAFB proteins significantly increased ITGB4 expression
(Figure 3(d)).
3.4. Malat-1: A ncRNA Target for SAF2? Another interesting
observation from the iCLIP dataset revealed significant
SAFB1 binding sites to metastasis associated lung adeno-
carcinoma transcript 1 (MALAT-1). MALAT-1 is a highly
conserved long ncRNA enriched in nuclear speckles that
6 BioMed Research International
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Figure 4: SAFB2 regulates expression of MALAT-1. (a) Expression of MALAT-1 was measured by qRT-PCR using RNA from MCF-7 and
MDA-MB-231 cells transfectedwith negative, SAFB1, SAFB2 or SAFB1 and SAFB2 siRNAusing validatedTaqManprobes specifically targeting
MALAT-1. Data represents the average of three biological replicates ± SD. Repeated Measures ANOVA with Dunnett’s Multiple Comparison
Test statistical significance of mRNA expression was calculated using Student’s 𝑡-test;𝑃 < 0.01. Enrichment ofMALAT1RNA by conventional
PCR (b) and qPCR (c) after RNA immunoprecipitation with anti-SAFB1 in MCF-7 cells. No enrichment was observed using IgG. (d)
Intranuclear distribution of SAFB1 and SRSF2 inMCF-7 cells by immunofluorescent staining. Confocal laser microscopy revealed a punctate
pattern for SAFB1 and SRSF2 in nuclear speckles.
regulates alternative splicing by modulating splicing factor
phosphorylation [18]. MALAT-1 is overexpressed in many
different cancers including breast and is considered an
oncogenic long ncRNA [19, 20]. We show that, in MCF-7
cells, loss of SAFB2 resulted in an increase in the levels of
MALAT-1 expression (Figure 4(a)). Moreover, we also tested
the ability of SAFBI to immunoprecipitateMALAT-1 RNA in
MCF-7 cells; enrichment ofMALAT-1RNAwas observed and
determined by conventional PCR and qPCR (Figures 4(b)
and 4(c)).
4. Discussion
The presence of the highly conserved RRMs within SAFB1
and SAFB2 proteins has been a subject of interest since
their discovery, especially in relation to their RNA-binding
potential. Despite the fascination, very little has been under-
taken until now to describe their RNA-binding capabilities.
Initial in vitro evidence showed that the RRM of SAFB1 is
able to bind RNA when glutathione S-transferase- (GST-)
tagged SAFB1 protein combined with total RNA fromMCF-7
cells generated a PCR product when reverse transcribed and
PCR amplified [8]. However, the identity of the RNA targets
was not described and important questions with respect to
the role of SAFB1 and SAFB2 in RNA processing remained
unanswered.
iCLIP has been proven as a powerful method to deter-
mine protein-RNA interactions in vivo on a global scale and
identify the positions of crosslink sites at nucleotide reso-
lution [11]. The random barcode incorporated to individual
cDNA molecules addresses the problem of PCR artifacts
faced by all high-throughput sequencing methods. iCLIP has
generated a huge dataset and this is an initial analysis of the
RNA-binding data for SAFB1. In this study, a global view
comparison of the complete dataset from each individual bio-
logical replicate showed that all datasets generated consistent
and reproducible results, underlining the high quality iCLIP
data achieved by high stringency purification and library
preparation.
The identification of in vivo targets by iCLIP enabled
the mapping of transcript regions and RNA classes bound
by SAFB1. An overview of the iCLIP results showed that
the important class of RNAs bound by SAFB1 was ncRNAs.
Interestingly, this binding distribution of SAFB1 is similar to
the RNA-binding distribution of splicing factors SRSF3 and
SRSF4 rather than hnRNP C protein; SAFB1 was initially
classified as a novel member of the hnRNP protein family
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[6]. Recent work by A¨nko¨ et al. utilised iCLIP to reveal that
concentrated SRSF3 and SRSF4 binding sites were also in
ncRNAs [21], while Ko¨nig et al. [11] showed that hnRNP
C binding sites were most abundant within introns [11].
This observation raises the possibility that SAFB1 protein
may have similar characteristics to SR proteins rather than
hnRNP protein members, although at this stage this is only
speculative.
The term ncRNA is commonly used for RNA that does
not encode a protein but appears to comprise internal signals
that control various levels of gene expression, including
chromatin organisation, transcription, RNA splicing, editing,
translation, and turnover (reviewed in [22]). Consistent with
already known functions of SAFB proteins, concentrated
SAFB1 binding in ncRNAs observed from the iCLIP data
could possibly contribute to its various role in chromatin
organisation, transcription, and RNA metabolism. Analysis
of SAFB1 distribution within ncRNA subclasses revealed
most abundant SAFB1 binding in snRNAs. snRNAs are a
class of small RNA molecules found to be uridylate-rich
and localised within the nucleus [23]. The most common
members of snRNAs are the U1, U2, U4, U5, and U6
snRNAs that form the spliceosome along with many other
protein factors and primarily function in pre-mRNA splicing
(reviewed in [24]). The high distribution of SAFB1 binding
sites in snRNAs observed in this study supports previously
identified interactions between SAFB1 with various RNA
processing factors and splicing machinery [1, 4, 6, 25].
The genome-wide, single nucleotide resolution of iCLIP
data enabled the prediction of in vivo consensus bind-
ing sequences for SAFB1 based on the enriched pentamer
sequences surrounding the crosslink sites. This study is the
first to report that SAFB1 binds a consensus adenine-rich
sequence in vivo. Closer examination of the putative con-
sensus binding sequence revealed the exclusion of thymine
(uracil in RNA) at base position 4 and a strong inclusion of
adenine at base position 5. Interestingly, the predicted SAFB1-
binding motif is not dissimilar to purine-rich sequences
found inRNA-bindingmotifs for other SR proteins (reviewed
in [26]).
When analysing SAFB1 crosslink sites within protein-
coding transcripts, SAFB1 binding density was also enriched
in regions encompassing the ORF and 3󸀠 and 5󸀠 UTR. The
list of RNA targets was filtered according to the region and
density of SAFB1 binding to identify targets that are relevant
to tumourigenesis. Several interesting genes were highlighted
in this study including SHF, ITGB4, andMALAT-1.
SHF is a member of a family of adaptor protein charac-
terised by their ability tomediate protein-protein interactions
through their Src homology 2 domain [27, 28]. Although
the function of SHF is not fully understood, evidence has
shown that overexpression of SHF significantly decreases the
rate of growth factor-induced apoptosis in neuroblastoma
cells [27]. Subsequently, Ohira et al. showed that SHFmRNA
was highly expressed in nonmetastatic neuroblastoma com-
pared to metastatic tumour samples [29]. Another recent
study provided evidence that loss of SHF increased cellular
mobility and the invasive capability of neuroblastoma cells
[30].
Initial iCLIP data from this study revealed enriched
SAFB1 binding sites at the alternative promoter of SHF. As
the aberrant expression of alternative promoters is linked
to cancer, SAFB1 binding surrounding this region gathered
an interest for further examination. Interestingly, the knock-
down of SAFB1 inMCF-7 cells did not significantly alter SHF
expression while the knockdown of SAFB2 or both SAFB
proteins significantly increased SHF expression.This suggests
that direct SAFB1 binding to the alternative promoter did not
affect the expression of this gene. MDA-MB-231 cells were
included in this part of the study for comparison and, in this
cell type, increased SHF expression was observed in the loss
of SAFB1 or SAFB2 and both SAFB proteins.
Multiple alternatively spliced transcript variants encod-
ing distinct isoforms have been found for ITGB4, although
the full function of most variants remains to be defined
[31–33]. Alternative splicing mechanism has been indicated
to subtly regulate the ligand binding and signalling activity
of many integrin subunits (reviewed in [34]). Although the
mechanism and significance of alternative splicing in ITGB4
have not been elucidated, the discovery of SAFB1 binding
sites in its exonic regions may provide a new perspective to
further understand the mRNA processing of ITGB4.
We also identified another potential novel target for
SAFB2—MALAT-1. Previous work shows that MALAT-1
colocalises with SRSF2 in nuclear speckles [35]. Furthermore,
other splicing factors that localise in nuclear speckles such
as SRSF1, SRSF3, and SRSF4 also bind to MALAT-1 [21,
36]. We, and others [1, 5], observe that SAFB1 distribution
has a similar punctate pattern to SRSF2 (Figure 4(d)); it is
therefore conceivable that SAFB1 may possess other typical
characteristics of a splicing factorwhich supports its observed
function in pre-mRNA splicing [1, 5, 7].
Interestingly, single depletion of either SAFB1 or SAFB2
led to an increase in expression of the other; this pattern
was mirrored at both mRNA and protein levels. Our study
also suggests that SAFBI and SAFB2 may themselves have
different and overlapping RNA targets.This observation sup-
ports previous speculations regarding the distinct molecular
roles between SAFB1 and SAFB2 [5, 37, 38]. We conclude
that SAFB proteins may share multiple similarities in RNA-
binding pattern and characteristics with SR proteins. Anal-
ysis of SAFB1 crosslink regions and RNA targets confirms
previous reports regarding its interaction with other RNA
processing machinery and function. Further work will now
be undertaken to define whether SAFB1 and SAFB2 function
synergistically or compensatory as RNA-binding proteins in
breast cancer cells.
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